Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

24.3K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
24.3K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reprogramming endogenous NK circuits by highly efficient nonviral genome editing.

The Journal of experimental medicine·2026
Same author

Manufacturing and clinical applications of non-CAR-T immune effector cells.

Transfusion·2026
Same author

CRISPR-engineered T-cell therapies: some clarifications needed - Authors' reply.

The Lancet. Oncology·2025
Same author

Treatment with Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome: A Double-Blind, Placebo-controlled, Multicenter Phase 2b Clinical Trial (STAT).

American journal of respiratory and critical care medicine·2025
Same author

Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Clinical manufacture of CRISPR/Cas9-based cytokine-induced SH2 protein knock-out tumor-infiltrating lymphocytes for gastrointestinal cancers.

Cytotherapy·2025

Related Experiment Video

Updated: Aug 18, 2025

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

18.9K

Development of allogeneic iPS cell-based therapy: from bench to bedside.

David H McKenna1,2, Rita C R Perlingeiro2,3

  • 1Molecular and Cellular Therapeutics, University of Minnesota, Saint Paul, MN, USA.

EMBO Molecular Medicine
|December 8, 2022
PubMed
Summary

Generating clinical-grade induced pluripotent stem (iPS) cell products requires careful documentation and optimized manufacturing. Ensuring product quality, cGMP compliance, and patient safety are paramount for successful iPS cell therapies.

More Related Videos

Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease
09:45

Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease

Published on: April 12, 2021

8.3K
Author Spotlight: Advancements in Cell and Tissue Engineering for Tendon Repair
04:48

Author Spotlight: Advancements in Cell and Tissue Engineering for Tendon Repair

Published on: March 1, 2024

1.9K

Related Experiment Videos

Last Updated: Aug 18, 2025

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
12:47

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

18.9K
Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease
09:45

Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease

Published on: April 12, 2021

8.3K
Author Spotlight: Advancements in Cell and Tissue Engineering for Tendon Repair
04:48

Author Spotlight: Advancements in Cell and Tissue Engineering for Tendon Repair

Published on: March 1, 2024

1.9K

Area of Science:

  • Regenerative Medicine
  • Stem Cell Biology
  • Biotechnology

Background:

  • Induced pluripotent stem (iPS) cells offer potential for cell-based therapies.
  • Clinical translation of iPS cell products necessitates robust manufacturing processes.
  • Current challenges include ensuring product consistency and regulatory compliance.

Purpose of the Study:

  • To outline the essential steps for generating clinical-grade iPS cell products.
  • To highlight the importance of documentation and process optimization.
  • To emphasize patient safety and regulatory adherence in iPS cell manufacturing.

Main Methods:

  • Systematic optimization of manufacturing methods.
  • Implementation of extensive and proper documentation.
  • Adherence to current good manufacturing practices (cGMP).
  • Focus on maintaining key biological features of the iPS cell product.

Main Results:

  • A framework for generating clinical-grade iPS cell products is presented.
  • The critical role of documentation and cGMP compliance is emphasized.
  • Strategies for scale-up, purification, isolation, and expansion are discussed.

Conclusions:

  • Successful clinical application of iPS cell products depends on rigorous manufacturing standards.
  • Patient safety is the primary consideration throughout the production process.
  • Standardized and optimized iPS cell manufacturing is key to advancing regenerative medicine.